Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Pain at 48 hours (VAS 0-10) · Adults (>18 years) with established dry socket following permanent tooth extraction
Topical anaesthetic gel (prilocaine-lidocaine) showed no clear difference in pain at 48 hours (VAS 0-10) compared with eugenol; GRADE not reported.
1 finding from 1 review
Time to initial pain relief (minutes) · Adults (>18 years) with established dry socket following permanent tooth extraction
Alvogyl led to lower time to initial pain relief (minutes) compared with zinc oxide eugenol; GRADE not reported.
1 finding from 1 review
Oral cytology (e.g. OralCDx brush biopsy, CytID) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative)
Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…
The review found no eligible studies for this question.
1 finding from 1 review
COE with blood/salivary (biomarker) analysis vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative)
Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…
The review found no eligible studies for this question.
1 finding from 1 review
Specificity for detection of oral cavity cancer/OPMD · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…
1 finding from 1 review
Summary of findings 4 (no pooled analysis): specificity 0.99 (95% CI 0.99 to 1.00), 1.00 (95% CI 0.91 to 1.00), and 0.72 (95% CI 0.63 to 0.80) across the 3 studies. Certainty VERY LOW.
3 studies · 3600 participants
Very low
Sensitivity for detection of oral cavity cancer/OPMD · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…
1 finding from 1 review
Summary of findings 4 (no pooled analysis): sensitivity 0.85 (95% CI 0.81 to 0.88), 0.82 (95% CI 0.57 to 0.96), and 0.94 (95% CI 0.70 to 1.00) across the 3 studies. Prevalence 12.2% to 30.9%. Certainty VERY LOW.
3 studies · 3600 participants
Very low
COE with light-based detection (e.g. ViziLite Plus, Microlux/DL, VELscope, Identafi 3000) vs Reference standard: examination and clinical evaluation by a physician/clinician with specialist knowledge or training (long-term follow-up accepted for those screened negative)
Outcome not reported · Apparently healthy adults not reporting symptoms of OPMD or OSCC, attending an organised screening or surveillance programme, or screened…
The review found no eligible studies for this question.
1 finding from 1 review
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Vessel patency (at end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Amputation · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review